Skip to content
NB EN
Nettsak

RSV vaccine in Norway 2026: almost NOK 2,700, best in weeks 28–32 – and a free programme proposed for July 2027

Pregnant women in Norway still need a prescription and must pay for the RSV vaccine themselves. FHI now advises weeks 28–32, yet only about half take it, and counties range from 28 to 50 per cent. Here is the price, the timing and what the proposed free programme means.

Håkon Berntsen 7 min read
Pregnant women in Norway need a prescription and pay for the RSV vaccine themselves – FHI advises weeks 28–32. Illustration: AI-generated.
Pregnant women in Norway need a prescription and pay for the RSV vaccine themselves – FHI advises weeks 28–32. Illustration: AI-generated. Illustrasjon: KI-generert

The RSV vaccine is not free in Norway as of November 2026: pregnant women need a doctor’s prescription and pay for it themselves, and at Boots the vaccine Abrysvo costs NOK 2,497.20 plus NOK 200 to have it given. The Norwegian Institute of Public Health (FHI) now advises getting it in weeks 28–32 of pregnancy, and the government has proposed a free programme for infants from 1 July 2027.

Key facts as of November 2026:

  • Cost: Abrysvo is NOK 2,497.20 at Boots, plus NOK 200 to administer it. The GP appointment for the prescription comes on top.
  • Free? No. The vaccine is not part of the publicly funded vaccination programme.
  • Best timing: weeks 28–32 of pregnancy (FHI, 30 October 2026). It is licensed for weeks 24 to 36.
  • Uptake: 51 per cent of women who gave birth in September 2026 had been vaccinated during pregnancy.
  • Free programme: proposed from 1 July 2027 – but it has not been decided whether it will be a vaccine for mothers or an antibody for babies.

What happened: from 0.3 to 51 per cent in under three years

RSV (respiratory syncytial virus) is a common respiratory virus that circulates every autumn and winter. In infants it is one of the most common causes of lower respiratory tract infections and hospital admissions, and the burden is heaviest in the first six months of life.

According to FHI (6 November 2026), vaccine coverage rose from 0.3 per cent among women who gave birth in January 2024 to 51 per cent among those who gave birth in September 2026, with a clear rise from August 2025. Among Norwegian-born mothers the figure was 61 per cent.

The gaps are wide. For births between January and September 2026, coverage ranged from 28 to 50 per cent across counties and from 14 to 71 per cent across Oslo’s districts, with Oslo highest overall. The figures come from a study in the journal Eurosurveillance that linked the Medical Birth Registry, the national vaccination register SYSVAK and the National Population Register.

Is the RSV vaccine free for pregnant women in Norway?

No. FHI has recommended the vaccine to all pregnant women since November 2025 to protect the baby, but it is not part of the publicly funded programme. Pregnant women “must currently get a prescription from a doctor and pay for the vaccine themselves”, FHI says.

The same goes for adults. FHI’s vaccination handbook states plainly that RSV vaccines are not covered by the public purse and must be paid for by the individual.

How much does the RSV vaccine cost, and where can I get it?

According to the Boots price list (checked on 15 November 2026), Abrysvo costs NOK 2,497.20, and having it administered costs NOK 200 (NOK 150 for members). Vitusapotek charges NOK 220 to give the jab. FHI put the price at “around NOK 2,500” in November 2025. At Boots prices the total comes to almost NOK 2,700, plus whatever the doctor’s appointment costs.

  1. Get a prescription from a doctor. Midwives cannot prescribe the RSV vaccine, so if you only see a midwife you still need a prescription from a doctor.
  2. Buy the vaccine. According to FHI, RSV vaccines can be ordered from FHI or from pharmacies.
  3. Have it given. At your GP or at a pharmacy that vaccinates – Vitusapotek says the RSV vaccine can be given in-store with a prescription.

When in pregnancy should you get the RSV vaccine?

Abrysvo is licensed for pregnant women between weeks 24 and 36. On 30 October 2026 FHI sharpened its advice: for the best possible effect, it recommends giving the vaccine between weeks 28 and 32.

In practice, most women get it later. “We see that most people get the vaccine in weeks 33–35 of pregnancy. Newer studies suggest that vaccination in weeks 28–32 is a better time,” says FHI senior medical officer Fredrik Skår. Vaccinating earlier gives antibodies more time to pass from mother to baby.

  • Leave at least two weeks between the whooping cough vaccine, recommended in week 24, and Abrysvo.
  • According to FHI, the RSV vaccine can be given at the same time as the flu vaccine.
  • It can be given after week 36, but may be less effective if given less than two weeks before birth.
  • A new dose is recommended in every pregnancy.

Only Abrysvo is used in pregnancy. The other RSV vaccine on the Norwegian market, Arexvy, is not recommended during pregnancy or breastfeeding, according to FHI.

How well does it work, and is it safe?

FHI’s handbook gives Abrysvo an estimated effectiveness against hospital admission with RSV of up to 70 per cent 90 days after birth and 55 per cent after 180 days.

Real-world figures from England are higher. According to the UK Health Security Agency (17 April 2026), vaccination at least two weeks before birth gave 81.3 per cent protection against hospital admission in the 2024/25 season. The study followed almost 300,000 babies.

In the licensing trial of around 7,400 pregnant women, 6 per cent of babies in the vaccine group were born prematurely, compared with 5 per cent in the control group. FHI notes that no safety signals have been seen in children up to 24 months of age. The most common side effects are pain at the injection site, headache and muscle pain, usually gone within two to three days. Talk to your GP or midwife about what is right for you.

Should older people get the RSV vaccine?

FHI does not recommend it for all older adults. According to the handbook, the RSV vaccine “can be considered” for adults aged 60 and over with underlying conditions. Its estimated effectiveness against RSV-confirmed respiratory infection is around 80 per cent over one season.

Older adults pay for it themselves too: Arexvy costs NOK 2,342.50 at Boots, plus the fee for giving it. See also who should get the Covid vaccine this winter, and what it costs.

Why does this matter for Norway?

Every year, between 1 and 2 per cent of all children under one are admitted to hospital with RSV, according to FHI (November 2025). FHI finds lower vaccine coverage in districts with lower median income, lower education levels and more residents born abroad.

England offers the vaccine from week 28 through its public programme, and coverage there reached 64.1 per cent among women who gave birth in November 2025. In Norway, protection costs each family close to NOK 2,700.

A public programme could pay for itself. In October 2025 the Norwegian Medical Products Agency (DMP) estimated that Abrysvo in the childhood immunisation programme could prevent 374–408 hospital admissions a year and save NOK 80–88 million in hospital costs, making a programme cost-saving or close to cost-neutral.

What happens next – will it be free from 1 July 2027?

In its 2027 budget, the government proposes “a free, national offer to protect infants against RSV” from 1 July 2027. According to the Ministry of Health and Care Services (7 October 2026), NOK 55 million is earmarked for 2027, with a full-year cost estimated at NOK 110 million in 2028.

The budget has not yet been passed, and procurement will start once parliament has approved the money. Minister of Health and Care Services Jan Christian Vestre says the aim is a fairer, more equal offer across the whole country.

The free programme may not be a vaccine for pregnant women at all. The government has not decided between a seasonal antibody for infants and a vaccine for mothers; the choice will be made through a tender. FHI is aiming for a publicly funded offer in time for the 2027/2028 RSV season. Long-acting antibodies are already on the market in Norway, but are only recommended for defined high-risk groups of infants.

For anyone due this winter, the vaccine is still out of pocket – and the RSV season, according to FHI, usually runs from November to April.

Frequently asked questions

Is the RSV vaccine free for pregnant women in Norway?

No, not as of November 2026. You need a doctor’s prescription and pay yourself. The government has proposed a free programme for infants from 1 July 2027.

In which week of pregnancy should I get the RSV vaccine?

FHI recommends weeks 28–32 for the best effect. The vaccine is licensed for weeks 24 to 36, and you should leave at least two weeks after the whooping cough vaccine.

How much does the RSV vaccine cost at a pharmacy?

Boots lists Abrysvo at NOK 2,497.20 plus NOK 200 to administer it (15 November 2026). The doctor’s appointment for the prescription is extra.

Do I need a new dose in my next pregnancy?

Yes. FHI recommends a new dose in every pregnancy.

Related stories